Healthcare provider profile · identity verified

Hugh John Prentice, MD

Family Practice · HAMPTON, NJ · NPI 1669526190

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	244	69
Levothyroxine Sodium	Levothyroxine Sodium	243	60
Amlodipine Besylate	Amlodipine Besylate	241	67
Alprazolam	Alprazolam	193	42
Rosuvastatin Calcium	Rosuvastatin Calcium	167	53
Prednisone	Prednisone	153	86
Metoprolol Succinate	Metoprolol Succinate	112	33
Omeprazole	Omeprazole	99	38
Losartan Potassium	Losartan Potassium	97	25
Metformin Hcl	Metformin Hcl	96	26
Metformin Hcl Er	Metformin Hcl	92	27
Hydrochlorothiazide	Hydrochlorothiazide	87	24
Candesartan Cilexetil	Candesartan Cilexetil	84	22
Tamsulosin Hcl	Tamsulosin Hcl	83	25
Trazodone Hcl	Trazodone Hcl	83	18
Zolpidem Tartrate	Zolpidem Tartrate	80	14
Allopurinol	Allopurinol	78	20
Tramadol Hcl	Tramadol Hcl	73	15
Gabapentin	Gabapentin	72	14
Montelukast Sodium	Montelukast Sodium	71	16
Pantoprazole Sodium	Pantoprazole Sodium	69	27
Escitalopram Oxalate	Escitalopram Oxalate	68	18
Duloxetine Hcl	Duloxetine Hcl	64	13
Lisinopril	Lisinopril	62	17
Sertraline Hcl	Sertraline Hcl	61	19
Potassium Chloride	Potassium Chloride	60	14
Paroxetine Hcl	Paroxetine Hcl	59	14
Furosemide	Furosemide	57	17
Famotidine	Famotidine	55	20
Fluticasone Propionate	Fluticasone Propionate	54	15
Ezetimibe	Ezetimibe	53	17
Albuterol Sulfate Hfa	Albuterol Sulfate	52	17
Bupropion Xl	Bupropion Hcl	51	suppressed
Eliquis	Apixaban	51	15
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	51	20
Clopidogrel	Clopidogrel Bisulfate	49	suppressed
Jardiance	Empagliflozin	48	11
Oxycodone Hcl	Oxycodone Hcl	43	suppressed
Celecoxib	Celecoxib	42	suppressed
Simvastatin	Simvastatin	42	15
Carvedilol	Carvedilol	40	12
Meloxicam	Meloxicam	39	17
Fluoxetine Hcl	Fluoxetine Hcl	38	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	38	11
Telmisartan	Telmisartan	36	suppressed
Ozempic	Semaglutide	35	12
Fluconazole	Fluconazole	34	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	34	12
Doxazosin Mesylate	Doxazosin Mesylate	29	suppressed
Ondansetron Hcl	Ondansetron Hcl	29	suppressed
Repaglinide	Repaglinide	29	suppressed
Azithromycin	Azithromycin	27	26
Irbesartan	Irbesartan	27	suppressed
Lorazepam	Lorazepam	27	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	27	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	26	16
Mounjaro	Tirzepatide	26	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	26	suppressed
Candesartan-Hydrochlorothiazid	Candesartan/Hydrochlorothiazid	25	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	25	20
Ibandronate Sodium	Ibandronate Sodium	25	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	24	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	23	19
Lansoprazole	Lansoprazole	23	suppressed
Levofloxacin	Levofloxacin	23	18
Pioglitazone Hcl	Pioglitazone Hcl	23	suppressed
Spironolactone	Spironolactone	23	suppressed
Synthroid	Levothyroxine Sodium	22	suppressed
Valacyclovir	Valacyclovir Hcl	22	suppressed
Clonazepam	Clonazepam	21	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	21	suppressed
Temazepam	Temazepam	21	suppressed
Finasteride	Finasteride	20	suppressed
Glipizide Er	Glipizide	20	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Morphine Sulfate Er	Morphine Sulfate	20	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	20	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	20	suppressed
Cefuroxime	Cefuroxime Axetil	19	16
Tizanidine Hcl	Tizanidine Hcl	19	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	18	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Farxiga	Dapagliflozin Propanediol	18	suppressed
Glipizide	Glipizide	18	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	17	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	17	suppressed
Fenofibrate	Fenofibrate	16	suppressed
Ibuprofen	Ibuprofen	16	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	16	suppressed
Pravastatin Sodium	Pravastatin Sodium	16	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	15	suppressed
Latanoprost	Latanoprost	15	suppressed
Ramipril	Ramipril	15	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	15	suppressed
Invokana	Canagliflozin	14	suppressed
Solifenacin Succinate	Solifenacin Succinate	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Myrbetriq	Mirabegron	13	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	12	suppressed
Pregabalin	Pregabalin	12	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	12	suppressed
Colchicine	Colchicine	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Valsartan	Valsartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error